Pharmamarketeer
wet- en regelgeving

EMA committee recommends approval of Merck’s Zerbaxa 3g dose to treat adults with HAP, including VAP

12 augustus 2019
Pharma Biz

Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Zerbaxa 3g dose

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)